High-Tech Gründerfonds and Technologiegründerfonds Sachsen support enabling human biology in vitro with an investment in Dresden start-up denovoMATRIX
December 11, 2018
denovoMATRIX develops and manufactures biomimetic coatings for stem cell culture. With its technology, the team of denovoMATRIX enables cutting edge research in the stem cell field, and aims to revolutionize cell culture processes in Life Science research. The HTGF together with TGFS are participating in the seed financing round to support the growing denovoMATRIX team, and the launch of denovoMATRIX products into the market.
In recent months, denovoMATRIX has received great feedback and support from industry experts, winning the Innovation prize from IQ-Mitteldeutschland Life Science Cluster. ‘’Although we are pleased with our performance at various businessplan competitions, we are currently focusing our attention on our myMATRIX product line, designed for streamlining cell culture processes using defined, serum-free conditions’’ explains the CEO of denovoMATRIX, Dejan Husman. The start-up already has their first product line – the screenMATRIX – available for purchase through their website. It is a tool designed for researchers interested in discovering the ideal conditions for culturing their cells.
Dr. Fabian Mohr, Investment Manager at HTGF: “In order to be able to offer high-quality stem cell therapies in the future, manufacturers must keep their variability in cell cultivation low. denovoMATRIX products offer a chemically defined solution to this problem, which we hope will provide a good basis for the translation of stem cell therapies from research into clinical practice.”
In August 2018, denovoMATRIX GmbH was founded as a spin-off of the Technical University of Dresden. With the support of the Bundesministerium für Wirtschaft und Energie (BMWi) funding program EXIST Transfer of Research, the founders were able to commercialize the technology developed at the B CUBE – Center for Molecular Bioengineering. The vision of denovoMATRIX is to enable human biology in vitro – a broad mission to foster research in cell culture, and accelerate the implementation of cell-based therapies for the treatment of diseases.
About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge 500 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, hardware and life sciences / chemistry.
This group also includes a number of success stories, such as Mister Spex, Rigontec, 6Wunderkinder, Next Kraftwerke and Cumulocity, as well as Juniqe, an online shop for art enthusiasts. To date, external investors have injected over EUR 1.9 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests by now 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.